ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Challenges of tuberculosis in cancer patients: insights from two hospitals in Madrid.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveTuberculosis (TB) and cancer share overlapping clinical features that may worsen outcomes when coexist. We aimed to characterize TB in cancer patients and identify predictors of TB-related mortality in a low TB-prevalence setting.
methodsWe conducted a 15 year retrospective cohort study (2010-2024) across two hospitals in Madrid. Patients with microbiologically confirmed TB during cancer treatment or within the preceding 2 years were included. Clinical and demographic variables were analyzed to identify factors associated with adverse outcomes.
resultsEighty-eight cancer patients were diagnosed with TB (median age 62.5 years); 70.5% were male and 17% were immigrants. Immunocompromising conditions were present in 61.3%. Solid tumors predominated (75%), with lung cancer being the most frequent. TB was diagnosed after cancer in 68.1% of cases, and 93.9% of isolates were drug susceptible. Atypical presentations were observed in 68.8% of patients. After excluding six cases of BCGitis, overall and TB-related mortality were 28.0% and 12.1%, respectively. Patients who died had longer diagnostic delays (185.82 vs 69.48 days, p=0.03). Synchronous diagnosis of TB and cancer emerged was the only independent predictor of mortality (p=0.01), whereas no TB-related deaths occurred when TB was incidentally detected during cancer reassessment. Among the 33 patients tested, a positive interferon gamma release assay (IGRA) was associated with better outcomes, potentially reflecting preserved immunity.
conclusionsTB in cancer patients frequently presents atypically and is associated with diagnostic delays and substantial mortality. Proactive and systematic diagnostic strategies are warranted. Negative or indeterminate IGRA results should not exclude active TB.
Indexed as
Identifiers
42371307What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.